BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9418879)

  • 1. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.
    Westendorf JJ; Yamamoto CM; Lenny N; Downing JR; Selsted ME; Hiebert SW
    Mol Cell Biol; 1998 Jan; 18(1):322-33. PubMed ID: 9418879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
    Meyers S; Lenny N; Sun W; Hiebert SW
    Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
    Lutterbach B; Sun D; Schuetz J; Hiebert SW
    Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon.
    Shimizu K; Kitabayashi I; Kamada N; Abe T; Maseki N; Suzukawa K; Ohki M
    Blood; 2000 Jul; 96(1):288-96. PubMed ID: 10891464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.
    Rhoades KL; Hetherington CJ; Rowley JD; Hiebert SW; Nucifora G; Tenen DG; Zhang DE
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11895-900. PubMed ID: 8876234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
    Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
    Lenny N; Meyers S; Hiebert SW
    Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
    Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
    Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation.
    Meyers S; Lenny N; Hiebert SW
    Mol Cell Biol; 1995 Apr; 15(4):1974-82. PubMed ID: 7891692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
    Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
    Gelmetti V; Zhang J; Fanelli M; Minucci S; Pelicci PG; Lazar MA
    Mol Cell Biol; 1998 Dec; 18(12):7185-91. PubMed ID: 9819405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
    Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
    Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
    Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.